American Thoracic Society - Sanofi Investor Call
sanofi
Multiple blockbuster opportunities to expand Sanofi's leadership
in specialty respiratory
Leadership today
DUPIXENT
(dupilumab) Injection 300mg
#1 in Specialty Respiratory
driven by Dupixent leadership
across:
Asthma (launched)
CRSWNP (launched)
COPD (positive Ph3 data)
Developing blockbuster opportunities
itepekimab
amlitelimab
rilzabrutinib
SAR'765
Promising data in hand for itepekimab and SAR'765 poised to
deliver towards goal of launching 3-5 new products with €2-5B
peak potential in second half of decade
First asthma readouts in 2024 on amlitelimab, rilzabrutinib to
confirm unique profiles and potential to expand beyond lead
indications
DupixentⓇ is under investigation in COPD and not yet approved by any regulatory agency to treat this indication
Itepekimab, amlitelimab, rilzabrutinib and SAR'765 are under investigation and not yet approved by any regulatory agency
48 ATS Investor CallView entire presentation